Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$34.48B
Close$
$28.80
8.5% downside
Current Fair Value
8.5% downsideOvervalued by 8.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $34.48 Billion |
|---|---|
| Enterprise Value | $34.46 Billion |
| Dividend Yield | $0.55 (1.78%) |
| Earnings per Share | $0.58 |
| Beta | -0.16 |
| Outstanding Shares | 1,111,064,535 |
Return
| Return on Equity | 7.86% |
|---|---|
| Return on Assets | 6.07% |
| Return on Invested Capital | 7.30% |
Valuation & Multiples
| P/E Ratio | 51.25 |
|---|---|
| PEG | -2882.08 |
| Price to Sales | 7.87 |
| Price to Book Ratio | 4.5 |
| Enterprise Value to Revenue | 7.33 |
| Enterprise Value to EBIT | 51.53 |
| Enterprise Value to Net Income | 51 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shenzhen Salubris Pharmaceuticals Co., Ltd.
4,087 employees
CEO: Jie Yan Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily ...